Trial Profile
A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2019
Price :
$35
*
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms CLARITY EXT; CLARITY EXTENSION
- Sponsors EMD Serono
- 12 Sep 2019 Results of a post-hoc analysis in patients enrolled in CLARITY and CLARITY Extension studies published in the Merck media release
- 28 Aug 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).
- 01 Jul 2019 Results assessing impact of non randomized droup out on treatment switching adjustment using CLARITY and CLARITY Extension trial published in the Value in Health